仑伐替尼与索拉非尼一线治疗肝细胞癌的成本-效益分析
Cost-effectiveness analysis of the first line treatment of hepatocellular carcinoma with lenvatinib and sorafenib
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 | 〉 |